Results 161 to 170 of about 4,098 (181)

Thyroid stimulating immunoglobulin concentration is associated with disease activity and predicts response to treatment with intravenous methylprednisolone in patients with Graves' orbitopathy. [PDF]

Front Endocrinol (Lausanne)
Hötte GJ, Kolijn PM, de Bie M, de Keizer ROB, Medici M, van der Weerd K, van Hagen PM, Paridaens D, Dik WA.   +8 more
europepmc   +1 more source

Late orbital radiotherapy combined with intravenous methylprednisolone in the management of long-lasting active graves' orbitopathy: a case report and literature review. [PDF]

Endocrine
Verrienti M, Gagliardi I, Valente L, Stefanelli A, Borgatti L, Franco E, Galiè M, Bondanelli M, Zatelli MC, Ambrosio MR.   +9 more
europepmc   +1 more source

Correction to "Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study".

J Clin Endocrinol Metab
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Current concepts regarding Graves’ orbitopathy

Journal of Internal Medicine, 2022
Luigi Bartalena, Maria Laura Tanda
exaly  

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy

Frontiers in Endocrinology, 2021
Sijie Fang, Peiwei Chai
exaly  

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy

Frontiers in Cellular and Infection Microbiology, 2021
Clara Saux, Danian Chen
exaly  

New insights into the pathogenesis and nonsurgical management of Graves orbitopathy

Nature Reviews Endocrinology, 2020
Peter N Taylor, Lei Zhang, Richard W J Lee   +2 more
exaly  

Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy

Frontiers in Endocrinology, 2020
Luigi Bartalena, Daniela Gallo, Maria Laura Tanda   +2 more
exaly